The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Open accessAbstract
The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch from extracellular signals to intracellular responses. Alterations of signaling cascades are found in various diseases, including cancer, as a result of genetic and epigenetic changes. Numerous studies focused on both the homeostatic and the pathologic conduct of MAPK signaling; however, there is still much to be deciphered in terms of regulation and action models in both preclinical and clinical research. MAPK has implications in the response to cancer therapy, particularly the activation of the compensatory pathways in response to experimental MAPK inhibition. The present paper discusses new insights into MAPK as a complex cell signaling pathway with roles in the sustenance of cellular normal conduit, response to cancer therapy, and activation of compensatory pathways. Unfortunately, most MAPK inhibitors trigger resistance due to the activation of compensatory feed-back loops in tumor cells and tumor microenvironment components. Therefore, novel combinatorial therapies have to be implemented for cancer management in order to restrict the possibility of alternative pathway activation, as a perspective for developing novel therapies based on integration in translational studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhou, S.-F., Li, J., Yang, Y., Liu, Q., Pan, S., He, Z., Zhang, X., Yang, T., Chen, X., Wang, D., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s75378 · Cited by 103
RetractedMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 4×
“Moreover, ECM regulates intercellular communication, cell junction plasticity, and cell adhesion molecules that interact with a wide range of cytokines/chemokine or growth factors [5,69,72,73].”
BackgroundInfluentialThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 1×
“This connection is therapeutically valuable and should be considered in developing novel therapies with an effect upon activated HIF-1α [81]; moreover, hypoxia regulates not only cancer progression through angiogenesis and metastasis but also the resistance to therapy [80].”
BackgroundThe Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Research works printed but not linked: 9
- Cainap, 2016, Results of third-generation epirubicin/cisplatin/xeloda adjuvant chemotherapy in patients with radically resected gastric cancer, J. BU ON, 21, 349
- Irimie, 2015, Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics, Acta Odontol. Scand., 73, 161, 10.3109/00016357.2014.986754 · doi:10.3109/00016357.2014.986754
- Zhao, 2017, MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing beta-catenin nuclear accumulation, Oncol. Rep., 38, 3055, 10.3892/or.2017.5955 · doi:10.3892/or.2017.5955
- Ionescu, 2014, TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: A pilot study, J. Gastrointest. Liver Dis., 23, 413, 10.15403/jgld.2014.1121.234.smad · doi:10.15403/jgld.2014.1121.234.smad
- Mauro, 2017, Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors, Sci. Rep., 7, 9388, 10.1038/s41598-017-10062-1 · doi:10.1038/s41598-017-10062-1
- Zou, 2019, Mechanisms shaping the role of ERK1/2 in cellular senescence, Mol. Med. Rep., 19, 759
- Tomuleasa, 2012, Sorafenib for advanced-stage hepatocellular carcinoma, Eur. J. Gastroenterol. Hepatol., 24, 346, 10.1097/MEG.0b013e3283501a2e · doi:10.1097/meg.0b013e3283501a2e
- Pall, 2011, Establishment of an embryonic stem cell line from blastocyst stage mouse embryos, Rom. J. Morphol. Embryol., 52, 1005
- Susman, 2011, Pancreatic exocrine adult cells and placental stem cells co-culture. Working together is always the best way to go, Rom. J. Morphol. Embryol., 52, 999
Cited by
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
Chamoli, A., Gosavi, A. S., Shirwadkar, U. P., Wangdale, K. V., Behera, S. K., Kurrey, N. K., Kalia, K., & Mandoli, A. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105451 · Cited by 589
Sugiura, R., Satoh, R., & Takasaki, T. (2021) · Cells · doi:10.3390/cells10102509 · Cited by 369
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Metadata
- Authors
- Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., Ionescu, C., & Berindan-Neagoe, I.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-10-22
- Volume
- 11
- Issue
- 10
- Pages
- 1618
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2982051641
- Cited by
- 944
- References
- 140
- FWCI
- 26.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. https://app.cochat.ai/papers/10.3390/cancers11101618
- The paper
- Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., Ionescu, C., & Berindan-Neagoe, I. (2019). A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers. https://doi.org/10.3390/cancers11101618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.